{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T12:34:39Z","timestamp":1793450079467,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Open Respiratory Archives"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.opresp.2026.100638","type":"journal-article","created":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T00:44:41Z","timestamp":1779583481000},"page":"100638","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evidence Update for Tezepelumab to Treat Severe Uncontrolled Asthma, Corticosteroid-dependent Asthma, Chronic Rhinosinusitis With Nasal Polyposis, and Chronic Obstructive Pulmonary Disease. 2nd Barcelona Respiratory Network report"],"prefix":"10.1016","volume":"8","author":[{"given":"Vicente","family":"Plaza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Ausin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Crespo-Lessmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Mu\u00f1oz-Esquerre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00cd\u00f1igo","family":"Ojanguren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.opresp.2026.100638_bib0245","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in adults with uncontrolled asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.opresp.2026.100638_bib0250","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s12931-020-01526-6","article-title":"NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma","author":"Menzies-Gow","year":"2020","journal-title":"Respir Res"},{"key":"10.1016\/j.opresp.2026.100638_bib0255","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.opresp.2026.100638_bib0260","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s12931-020-01513-x","article-title":"CASCADE: a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of tezepelumab on airway inflammation in patients with uncontrolled asthma","volume":"21","author":"Emson","year":"2020","journal-title":"Respir Res"},{"key":"10.1016\/j.opresp.2026.100638_bib0265","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S2213-2600(21)00226-5","article-title":"Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"9","author":"Diver","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.opresp.2026.100638_bib0270","article-title":"The effect of tezepelumab on airway hyperresponsiveness to mannitol in asthma (UPSTREAM)","volume":"59","author":"Sverrild","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.opresp.2026.100638_bib0275","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S2213-2600(22)00492-1","article-title":"Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study","volume":"11","author":"Menzies-Gow","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.opresp.2026.100638_bib0280","series-title":"Global strategy for asthma management and prevention","year":"2025"},{"key":"10.1016\/j.opresp.2026.100638_bib0285","unstructured":"GEMA 5.5. [Spanish Asthma Management Guidelines]. Gu\u00eda Espa\u00f1ola para el Manejo del Asma. Available from: http:\/\/www.gemasma.com. [Accessed 19 November 2025]."},{"key":"10.1016\/j.opresp.2026.100638_bib0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.opresp.2022.100231","article-title":"Efficacy and potential positioning of tezepelumab in the treatment of severe asthma","volume":"5","author":"Plaza","year":"2023","journal-title":"Open Respir Arch"},{"key":"10.1016\/j.opresp.2026.100638_bib0295","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1007\/s12325-025-03231-6","article-title":"Effectiveness and safety of tezepelumab in a diverse population of US patients with severe asthma: initial results of the PASSAGE study","volume":"42","author":"Lugogo","year":"2025","journal-title":"Adv Ther"},{"key":"10.1016\/j.opresp.2026.100638_bib0300","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1080\/02770903.2021.2010749","article-title":"Asthma biologic trial eligibility and real-world outcomes in the United States","volume":"59","author":"Lam","year":"2022","journal-title":"J Asthma"},{"key":"10.1016\/j.opresp.2026.100638_bib0305","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01444-2018","article-title":"Randomised controlled trials in severe asthma: selection by phenotype or stereotype","volume":"52","author":"Brown","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.opresp.2026.100638_bib0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2019.08.023","article-title":"Underrepresentation of blacks, smokers, and obese patients in studies of monoclonal antibodies for asthma","volume":"8","author":"Akenroye","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.opresp.2026.100638_bib0315","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/j.jaci.2018.11.022","article-title":"Racial disparities in asthma-related health care use in the National Heart, Lung, and Blood Institute's Severe Asthma Research Program","volume":"143","author":"Fitzpatrick","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.opresp.2026.100638_bib0320","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1080\/14728222.2020.1783242","article-title":"Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma","volume":"24","author":"Gauvreau","year":"2020","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.opresp.2026.100638_bib0325","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1016\/j.jaip.2022.05.042","article-title":"REALITI-A study: real-world oral corticosteroid-sparing effect of mepolizumab in severe asthma","volume":"10","author":"Pilette","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.opresp.2026.100638_bib0330","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01521-2023","article-title":"Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme","volume":"64","author":"Jackson","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.opresp.2026.100638_bib0335","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2147\/JAA.S342391","article-title":"Tezepelumab for severe asthma: one drug targeting multiple disease pathways and patient types","volume":"17","author":"Panettieri","year":"2024","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.opresp.2026.100638_bib0340","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.01593-2025","article-title":"Improvements in small airway dysfunction and respiratory symptoms following tezepelumab for severe asthma","author":"Kupershmidt","year":"2026","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.opresp.2026.100638_bib0345","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S2213-2600(21)00537-3","article-title":"Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study","volume":"10","author":"Wechsler","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.opresp.2026.100638_bib0350","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S2213-2600(25)00359-5","article-title":"Oral corticosteroid reduction and discontinuation in adults with corticosteroid-dependent, severe, uncontrolled asthma treated with tezepelumab (WAYFINDER): a multicentre, single-arm, phase 3b trial","volume":"14","author":"Jackson","year":"2026","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.opresp.2026.100638_bib0355","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00314-2025","article-title":"Real-world evidence of tezepelumab for severe asthma: a retrospective multicentre cohort","volume":"11","author":"Khateeb","year":"2025","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.opresp.2026.100638_bib0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2024.05.052","article-title":"Real-world data on tezepelumab in patients with severe asthma in Germany","volume":"12","author":"Biener","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.opresp.2026.100638_bib0365","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1152\/jappl.2000.88.3.1043","article-title":"Integrated response of the upper and lower respiratory tract of asthmatic subjects to frigid air","volume":"88","author":"McLane","year":"2000","journal-title":"J Appl Physiol (1985)"},{"key":"10.1016\/j.opresp.2026.100638_bib0370","doi-asserted-by":"crossref","first-page":"317","DOI":"10.18176\/jiaci.0910","article-title":"Spanish Consensus on the Management of Chronic Rhinosinusitis with Nasal Polyps (POLIposis NAsal\/POLINA 2.0)","volume":"33","author":"Alobid","year":"2023","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.opresp.2026.100638_bib0375","first-page":"287","article-title":"EPOS2020\/EUFOREA expert opinion on defining disease states and therapeutic goals in CRSwNP","volume":"62","author":"Fokkens","year":"2024","journal-title":"Rhinology"},{"key":"10.1016\/j.opresp.2026.100638_bib0380","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2500\/ajra.2016.30.4304","article-title":"Asthma in ear, nose, and throat primary care patients with chronic rhinosinusitis with nasal polyps","volume":"30","author":"Frend\u00f8","year":"2016","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.opresp.2026.100638_bib0385","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/alr.21674","article-title":"Prevalence of confirmed asthma varies in chronic rhinosinusitis subtypes","volume":"6","author":"Promsopa","year":"2016","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.opresp.2026.100638_bib0390","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12931-018-0823-y","article-title":"Prevalence of asthma, aspirin sensitivity and allergy in chronic rhinosinusitis: data from the UK National Chronic Rhinosinusitis Epidemiology Study","volume":"19","author":"Philpott","year":"2018","journal-title":"Respir Res"},{"key":"10.1016\/j.opresp.2026.100638_bib0395","first-page":"7","article-title":"The nose\u2013lung interaction in allergic rhinitis and asthma: united airways disease","volume":"1","author":"Passalacqua","year":"2001","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.opresp.2026.100638_bib0400","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1007\/s12325-025-03120-y","article-title":"Real-world outcomes following biologic initiation in US patients with chronic rhinosinusitis with nasal polyps","volume":"42","author":"Peters","year":"2025","journal-title":"Adv Ther"},{"key":"10.1016\/j.opresp.2026.100638_bib0405","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1939-4551-7-25","article-title":"ICON: chronic rhinosinusitis","volume":"7","author":"Bachert","year":"2014","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.opresp.2026.100638_bib0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2019.05.009","article-title":"Associations between inflammatory endotypes and clinical presentations in chronic rhinosinusitis","volume":"7","author":"Stevens","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.opresp.2026.100638_bib0415","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/all.15986","article-title":"Tezepelumab in patients with allergic and eosinophilic asthma","volume":"79","author":"Caminati","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.opresp.2026.100638_bib0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2013.04.005","article-title":"Thymic stromal lymphopoietin activity is increased in nasal polyps of patients with chronic rhinosinusitis","volume":"132","author":"Nagarkar","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.opresp.2026.100638_bib0425","doi-asserted-by":"crossref","first-page":"186","DOI":"10.4168\/aair.2011.3.3.186","article-title":"Increased expression and role of thymic stromal lymphopoietin in nasal polyposis","volume":"3","author":"Kimura","year":"2011","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.opresp.2026.100638_bib0430","doi-asserted-by":"crossref","first-page":"915","DOI":"10.2147\/JAA.S413064","article-title":"Tezepelumab efficacy in patients with severe, uncontrolled asthma with comorbid nasal polyps in NAVIGATOR","volume":"16","author":"Laidlaw","year":"2023","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.opresp.2026.100638_bib0435","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1056\/NEJMoa2414482","article-title":"Tezepelumab in adults with severe chronic rhinosinusitis with nasal polyps","volume":"392","author":"Lipworth","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.opresp.2026.100638_bib0440","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2025 GOLD report. Available from: https:\/\/goldcopd.org\/2025-gold-report\/. [Accessed 19 September 2025]."},{"key":"10.1016\/j.opresp.2026.100638_bib0445","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1093\/bmb\/ldaa043","article-title":"The different phenotypes of COPD","volume":"137","author":"Yousuf","year":"2021","journal-title":"Br Med Bull"},{"key":"10.1016\/j.opresp.2026.100638_bib0450","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2303951","article-title":"Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts","volume":"389","author":"Bhatt","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.opresp.2026.100638_bib0455","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1056\/NEJMoa2401304","article-title":"Dupilumab for COPD with blood eosinophil evidence of type 2 inflammation","volume":"390","author":"Bhatt","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.opresp.2026.100638_bib0460","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1905248","article-title":"Benralizumab for the prevention of COPD exacerbations","volume":"381","author":"Criner","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.opresp.2026.100638_bib0465","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S2213-2600(19)30338-8","article-title":"Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies","volume":"8","author":"Criner","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.opresp.2026.100638_bib0470","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S2213-2600(24)00324-2","article-title":"Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial","volume":"13","author":"Singh","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.opresp.2026.100638_bib0475","unstructured":"EMBARK. A randomised, double-blind, placebo-controlled, parallel group, multicentre, phase III study to evaluate the efficacy and safety of tezepelumab in adult participants with moderate to very severe chronic obstructive pulmonary disease (D5241C00006) ClinicalTrials.gov identifier: NCT06883305. Last updated: 7 May 2026 https:\/\/clinicaltrials.gov\/study\/NCT06883305. [Accessed 12 May 2026]."},{"key":"10.1016\/j.opresp.2026.100638_bib0480","unstructured":"JOURNEY. A randomised, double-blind, placebo-controlled, parallel group, multicentre, phase III study to evaluate the efficacy and safety of tezepelumab in adult participants with moderate to very severe chronic obstructive pulmonary disease (D5241C00007) ClinicalTrials.gov identifier: NCT06878261. Last updated: 7 May 2026 https:\/\/clinicaltrials.gov\/study\/NCT06878261. [Accessed 12 May 2026]."}],"container-title":["Open Respiratory Archives"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2659663626001025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2659663626001025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T12:18:19Z","timestamp":1793449099000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2659663626001025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2659663626001025"],"URL":"https:\/\/doi.org\/10.1016\/j.opresp.2026.100638","relation":{},"ISSN":["2659-6636"],"issn-type":[{"value":"2659-6636","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evidence Update for Tezepelumab to Treat Severe Uncontrolled Asthma, Corticosteroid-dependent Asthma, Chronic Rhinosinusitis With Nasal Polyposis, and Chronic Obstructive Pulmonary Disease. 2nd Barcelona Respiratory Network report","name":"articletitle","label":"Article Title"},{"value":"Open Respiratory Archives","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.opresp.2026.100638","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Sociedad Espa\u00f1ola de Neumolog\u00eda y Cirug\u00eda Tor\u00e1cica (SEPAR). Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"100638"}}